论文部分内容阅读
血脂紊乱、尤其是血总胆固醇(TC)升高及低密度脂蛋白胆固醇(LDL-C)升高为冠状动脉粥样硬化性心脏病(冠心病)的主要危险因素。长期控制血脂(TC及LDL-C)水平,可以减缓冠心病的发生和发展,因而降低其发病率和死亡率,故调脂治疗为目前冠心病Ⅰ级预防和Ⅱ级预防的热点。国外已有大规模的临床试验(如4S、Plac-Ⅰ、Regress等试验)证明,3羟基-3甲基戊二酰辅酶A(HMG-CoA)还
Dyslipidemia, especially elevated blood total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) are the major risk factors for coronary atherosclerotic heart disease (CHD). Long-term control of blood lipids (TC and LDL-C) levels can slow down the occurrence and development of coronary heart disease, thereby reducing its morbidity and mortality. Therefore, lipid-regulating therapy is currently the focus of Class I prevention and Class II prevention of coronary heart disease. Large-scale clinical trials in foreign countries (such as 4S, Plac-I, Regress, etc.) have proved that 3 hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)